Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
WASHINGTON, April 22, 2024 /PRNewswire/ --Vanda Pharmaceuticals, Inc.. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ® Abbreviated New Drug Application litigation …